PMDA drug package insert
カルボプラチン点滴静注液50mg「NK」
PMDA Prescription drug · ヴィアトリス・ヘルスケア合同会社 · package insert Jul 14, 2026
Key facts
| Brand names | カルボプラチン点滴静注液50mg「NK」, カルボプラチン点滴静注液150mg「NK」, カルボプラチン点滴静注液450mg「NK」 |
|---|---|
| Nonproprietary names | カルボプラチン |
| Companies | 製造販売元／ヴィアトリス・ヘルスケア合同会社, 発売元／日本化薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤 |
| Therapeutic category codes | 874291 |
| YJ codes | 4291403A1096, 4291403A2092, 4291403A3099 |
| Approval numbers | 22000AMX01442, 22000AMX01443, 22000AMX01444 |
| Package insert edition | 第8版 |
| Package insert date | Jul 14, 2026 |
| PMDA document key | 730869_4291403A1096_7 |
| PMDA company code | 730869 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: